Eli Lilly and Co. has filed a complaint with the U.S. International Trade Commission (ITC) against Hospira Inc., Intas Pharmaceuticals Ltd., and others, over attempts to introduce generic versions of the cancer drug Gemzar®. Lilly's complaint, filed Thursday, asks the ITC to launch an investigation into whether Hospira, Intas, Jiangsu Hansoh Pharmaceutical Co. Ltd., and Chem Werth Inc., have run afoul of Section 337 of the Tariff Act of 1930 in connection with the selling or importing of gemcitabine and gemcitabine-containing products that allegedly infringe Lilly's patent for Gemzar®. The complaint states that Hospira has contracts with the other three respondents to make and formulate a generic gemcitabine product for import and sale into the U.S., and requests permanent exclusion and cease-and-desist orders. Lilly is represented by Finnegan.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Justin A. Hendrix
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Justin A. Hendrix
September 18, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.